Drug Profile

RK 023

Alternative Names: Nobiprostolan; RK-023

Latest Information Update: 21 Feb 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator R-Tech Ueno
Developer Mallinckrodt plc; Sucampo Pharmaceuticals
Class Fatty acids
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Male pattern baldness
No development reported Hypotrichosis

Most Recent Events

13 Feb 2018 Sucampo Pharmaceuticals has been acquired and merged into Mallinckrodt plc
04 Nov 2017 No recent reports of development identified for phase-I development in Hypotrichosis(In volunteers) in Japan (Topical, Liquid)
07 Dec 2015 R-Tech Ueno has been acquired and merged into Sucampo Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com